$90 Million - Initial Public OfferingJoint Bookrunner
$41 Million - Follow-OnSole Bookrunner
Achillion Pharmaceuticals Inc.
$51 Million - Secondary OfferingJoint Bookrunner
Biopharma / AML – Will All the New Drugs Amount to More Than Niches?
SCMP / Attractive Risk/Reward with Amitiza and Two Rare Disease Oppy’s; Resume OP / Outperform
Hospital Utility Survey: Upside for MCOs, Earnings Achievability for Hospitals